Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/212266
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jácome, Dayaneth | - |
dc.contributor.author | Cotrufo, Tiziana | - |
dc.contributor.author | Andrés Benito, Pol | - |
dc.contributor.author | Lidón Gil, Laia | - |
dc.contributor.author | Martí Puig, Eulàlia | - |
dc.contributor.author | Ferrer, Isidro (Ferrer Abizanda) | - |
dc.contributor.author | Río Fernández, José Antonio del | - |
dc.contributor.author | Gavín Marín, Rosalina | - |
dc.date.accessioned | 2024-05-31T13:39:01Z | - |
dc.date.available | 2024-05-31T13:39:01Z | - |
dc.date.issued | 2024-06- | - |
dc.identifier.issn | 0925-4439 | - |
dc.identifier.uri | http://hdl.handle.net/2445/212266 | - |
dc.description.abstract | Clinical relevance of miRNAs as biomarkers is growing due to their stability and detection in biofluids. In this, diagnosis at asymptomatic stages of Alzheimer's disease (AD) remains a challenge since it can only be made at autopsy according to Braak NFT staging. Achieving the objective of detecting AD at early stages would allow possible therapies to be addressed before the onset of cognitive impairment. Many studies have determined that the expression pattern of some miRNAs is dysregulated in AD patients, but to date, none has been correlated with downregulated expression of cellular prion protein (PrPC) during disease progression. That is why, by means of cross studies of miRNAs up-regulated in AD with in silico identification of potential miRNAs-binding to 3'UTR of human PRNP gene, we selected miR-519a-3p for our study. Then, in vitro experiments were carried out in two ways. First, we validated miR-519a-3p target on 3'UTR-PRNP, and second, we analyzed the levels of PrPC expression after using of mimic technology on cell culture. In addition, RT-qPCR was performed to analyzed miR-519a-3p expression in human cerebral samples of AD at different stages of disease evolution. Additionally, samples of other neurodegenerative diseases such as other non-AD tauopathies and several synucleinopathies were included in the study. Our results showed that miR-519a-3p overlaps with PRNP 3'UTR in vitro and promotes downregulation of PrPC. Moreover, miR-519a-3p was found to be up-regulated exclusively in AD samples from stage I to VI, suggesting its potential use as a novel label of preclinical stages of the disease. | - |
dc.format.extent | 8 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier B.V. | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1016/j.bbadis.2024.167187 | - |
dc.relation.ispartof | Biochimica et Biophysica Acta-Molecular Basis of Disease, 2024, vol. 1870, num.5 | - |
dc.relation.uri | https://doi.org/10.1016/j.bbadis.2024.167187 | - |
dc.rights | cc-by-nc (c) Jácome, Dayaneth et al., 2024 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/es/ | * |
dc.source | Articles publicats en revistes (Biologia Cel·lular, Fisiologia i Immunologia) | - |
dc.subject.classification | Micro RNAs | - |
dc.subject.classification | Malaltia d'Alzheimer | - |
dc.subject.classification | Indicadors biològics | - |
dc.subject.other | MicroRNAs | - |
dc.subject.other | Alzheimer's disease | - |
dc.subject.other | Indicators (Biology) | - |
dc.title | miR-519a-3p, found to regulate cellular prion protein during Alzheimer’s disease pathogenesis, as a biomarker of asymptomatic stages | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 747921 | - |
dc.date.updated | 2024-05-31T13:39:06Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
Appears in Collections: | Articles publicats en revistes (Biologia Cel·lular, Fisiologia i Immunologia) Articles publicats en revistes (Institut de Bioenginyeria de Catalunya (IBEC)) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
858756.pdf | 1.6 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License